The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cn19:05 ET

Xiwang Foodstuffs Vice Chairman Sun Xinguo: The scale of the rapeseed oil business is expanding, and the sports nutrition product business is in a transformation stage. | Interview with Finance Specialist

①With the decline in prices of raw materials such as corn and protein, xiwang foodstuffs achieved high growth in performance in the first three quarters. The fourth quarter is the traditional peak season for corn oil, and it is expected that profits will further improve. ②The company's sports nutrition business has begun to grow steadily. In the first half of this year, the revenue share of xiwang foodstuffs' sports nutrition business accounted for nearly half, with a gross margin of 30.47%. The company plans to develop 2-3 major single products within two years.

cls.cnNov 8, 2024 09:14 ET

The pesticide market downturn dragged aba chemicals corporation into losses for five consecutive quarters, but the amount of losses narrowed. Interpretations of financial statements.

①Aba Chemicals Corporation has been operating at a loss for five consecutive quarters in Q3, but the amount of loss has narrowed compared to the first two quarters of this year. ② The pesticide industry is still at a low level, and the market situation for the company's main product, chlorfenapyr intermediate, has dropped significantly within one year. ③ The company's top ten shareholders changed in Q3, with a new institution shareholder and 'northbound funds' entering.

cls.cnOct 23, 2024 11:16 ET

Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations

①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.

cls.cnAug 23, 2024 08:58 ET

The suspected pollution of Erkang Pharmaceuticals' Cambodian factory was evicted due to a local request and an announcement will be made later

Serious pollution

Wallstreet NewsAug 15, 2023 05:37 ET

Ligand Pharmaceuticals Collaborates With China Resources Double-Crane to Develop Oral COVID-19 Therapeutic

MT NewswiresOct 21, 2021 10:33 ET